{"entity":{"id":"mansoor-raza-mirza","kind":"person","name":"Mansoor Raza Mirza","aka":[],"tldr":"Led NOVA and RUBY, the trials that established niraparib maintenance in ovarian cancer and dostarlimab in advanced endometrial cancer.","summary":"Mansoor Raza Mirza was principal investigator of NOVA, the first trial showing PARP inhibitor maintenance (niraparib) benefits recurrent ovarian cancer regardless of BRCA status, and of RUBY, which showed dostarlimab plus chemotherapy improves survival in primary advanced or recurrent endometrial cancer, most dramatically in mismatch repair-deficient disease. He chairs ENGOT and leads the Nordic Society of Gynaecological Oncology trial unit.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mirza%20MR%5BAuthor%5D%20niraparib%20OR%20dostarlimab"}],"tags":["endometrial","ovarian","trialist"],"related":[],"cancers":["endometrial","ovarian"],"sections":[],"technologies":["parp-inhibitor","checkpoint-inhibitor"],"targets":["parp","pd1"],"drugs":["niraparib","dostarlimab"],"companies":["nordic-lymphoma-group"],"institutions":["rigshospitalet"],"pathways":[],"terms":[],"trials":["ruby"],"people":[],"bottlenecks":[],"keyPapers":["paper-ruby-nejm-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Oncologist, Rigshospitalet, Copenhagen University Hospital; Chair, ENGOT","institutionId":"rigshospitalet","specialisms":["Endometrial cancer","Ovarian cancer","PARP inhibitors","Immunotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mirza%20MR%5BAuthor%5D%20niraparib%20OR%20dostarlimab"}],"papers":[{"title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer (NOVA)","journal":"NEJM","year":2016,"doi":"10.1056/NEJMoa1611310"},{"title":"Dostarlimab for primary advanced or recurrent endometrial cancer (RUBY)","journal":"NEJM","year":2023,"doi":"10.1056/NEJMoa2216334"}],"orcid":"0000-0002-8085-1010"},"route":"/people/mansoor-raza-mirza/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"dostarlimab","kind":"drug","name":"Dostarlimab","route":"/drugs/dostarlimab/"},{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/"}],"company":[{"id":"nordic-lymphoma-group","kind":"company","name":"Nordic Lymphoma Group","route":"/companies/nordic-lymphoma-group/"}],"institution":[{"id":"rigshospitalet","kind":"institution","name":"Rigshospitalet, Copenhagen University Hospital","route":"/institutions/rigshospitalet/"}],"trial":[{"id":"ruby","kind":"trial","name":"RUBY / ENGOT-EN6 / GOG-3031","route":"/trials/ruby/"}],"paper":[{"id":"paper-ruby-nejm-2023","kind":"paper","name":"RUBY: dostarlimab with chemotherapy for advanced or recurrent endometrial cancer","route":"/key-papers/paper-ruby-nejm-2023/"}]}}